DE602006015508D1 - Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs - Google Patents

Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs

Info

Publication number
DE602006015508D1
DE602006015508D1 DE602006015508T DE602006015508T DE602006015508D1 DE 602006015508 D1 DE602006015508 D1 DE 602006015508D1 DE 602006015508 T DE602006015508 T DE 602006015508T DE 602006015508 T DE602006015508 T DE 602006015508T DE 602006015508 D1 DE602006015508 D1 DE 602006015508D1
Authority
DE
Germany
Prior art keywords
treatment
prevention
pharmaceutical composition
glycoproteins
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015508T
Other languages
English (en)
Inventor
Bennink Herman Coelingh
Visser Monique
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantarhei Bioscience BV
Original Assignee
Pantarhei Bioscience BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience BV filed Critical Pantarhei Bioscience BV
Publication of DE602006015508D1 publication Critical patent/DE602006015508D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/892Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006015508T 2005-11-16 2006-11-16 Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs Active DE602006015508D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73687705P 2005-11-16 2005-11-16
EP05110819 2005-11-16
PCT/NL2006/050289 WO2007058536A1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer

Publications (1)

Publication Number Publication Date
DE602006015508D1 true DE602006015508D1 (de) 2010-08-26

Family

ID=37686152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015508T Active DE602006015508D1 (de) 2005-11-16 2006-11-16 Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs

Country Status (8)

Country Link
US (1) US7968514B2 (de)
EP (1) EP1951283B1 (de)
CN (1) CN101365473B (de)
AT (1) ATE473756T1 (de)
CA (1) CA2630175C (de)
DE (1) DE602006015508D1 (de)
PL (1) PL1951283T3 (de)
WO (1) WO2007058536A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586774C2 (ru) * 2010-08-27 2016-06-10 Пантархей Байосайенс Б.В. Иммунотерапевтический способ лечения рака простаты
US20150110897A1 (en) * 2011-09-15 2015-04-23 University Of Southern California Sperm Protein as a Detection Biomarker of Early Stage Ovarian Cancer
CN104804075A (zh) * 2014-01-24 2015-07-29 中南大学 变异的人卵透明带蛋白1和突变基因及检测方法和应用
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
US20210317165A1 (en) 2018-09-03 2021-10-14 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
JPH0799974A (ja) * 1993-10-05 1995-04-18 Tonen Corp ヒト卵透明帯−2蛋白質をコードするdna
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CN1291229A (zh) 1998-02-19 2001-04-11 东弗吉尼亚医学院 重组的活性人透明带蛋白3
US6455041B1 (en) * 1998-11-17 2002-09-24 Bonita S. Dunbar Immunogenic epitopes of the human zona pellucida protein (ZP1)
CA2378472A1 (en) 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Method and composition for affecting reproductive systems
US6455941B1 (en) * 2001-01-03 2002-09-24 Advanced Semiconductor Engineering, Inc. Chip scale package
BRPI0414446A (pt) 2003-09-18 2006-11-14 Genmab As métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide

Also Published As

Publication number Publication date
EP1951283A1 (de) 2008-08-06
CA2630175C (en) 2018-10-23
CA2630175A1 (en) 2007-05-24
CN101365473A (zh) 2009-02-11
EP1951283B1 (de) 2010-07-14
PL1951283T3 (pl) 2010-12-31
ATE473756T1 (de) 2010-07-15
US20090060931A1 (en) 2009-03-05
US7968514B2 (en) 2011-06-28
WO2007058536A1 (en) 2007-05-24
CN101365473B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
PH12020550258A1 (en) Trispecific proteins and methods of use
WO2006081826A3 (en) Survivin peptide vaccine
CY1119127T1 (el) Επιτοποι σκληροστινης
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
EA201000424A1 (ru) Антитела к il-23
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
EA201200515A1 (ru) Полипептиды и их применение
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
PH12021551372A1 (en) Human alpha-galactosidase variants
ATE449612T1 (de) Zusammensetzung zur impfung
PT1290160E (pt) Polipeptideos pellino humanos